13F Holdings
中文EN

CGEM Cullinan Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1789972 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-55.5%
ROA-50.4%
ROIC (approx.)-63.9%
Asset turnover—

Leverage & solvency

Liabilities / assets12.8%
Debt / equity0.00x
Current ratio7.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$0$18.94M
R&D expense$187.40M$142.90M$148.16M$91.95M$57.75M
SG&A expense$54.25M$54.02M$42.49M$40.19M$29.15M
Operating income-$241.65M-$196.92M-$191.09M$144.65M-$67.95M
Pretax income-$219.88M-$167.46M-$169.22M$151.32M-$67.48M
Income tax$0$117,000-$14.12M$42.12M$0
Net income-$219.88M-$167.38M-$153.16M$111.21M-$65.57M
EBITDA-$241.34M-$196.61M-$190.78M$144.74M-$67.90M
EPS (basic)——-3.692.46-1.52
EPS (diluted)——-3.692.38-1.52
Weighted avg. shares (diluted)——41.55M46.64M43.08M
Balance sheet
Cash & equivalents$88.33M$83.00M$98.43M$156.15M$59.77M
Short-term investments$289.56M$315.97M$368.63M$311.14M$230.69M
Current assets$386.76M$414.67M$480.19M$474.47M$296.56M
PP&E, net$421,000$683,000$989,000$1.17M$77,000
Total assets$448.37M$621.82M$484.18M$561.12M$437.19M
Current liabilities$37.74M$30.65M$28.14M$22.50M$11.75M
Total liabilities$39.64M$31.50M$30.29M$26.09M$11.81M
Shareholders' equity$408.73M$590.33M$453.70M$535.03M$424.97M
Shares outstanding60.24M58.51M42.90M45.80M44.29M
Cash flow statement
Operating cash flow-$175.75M-$145.30M-$134.28M-$126.66M-$43.43M
Capital expenditure$49,000$0$208,000$1.13M$0
Free cash flow-$175.80M-$145.30M-$134.48M-$127.80M-$43.43M
Investing cash flow$179.99M-$136.31M$35.81M$248.97M-$333.77M
Financing cash flow$1.09M$266.19M$40.75M-$25.93M$268.78M
Depreciation & amortization$311,000$306,000$310,000$93,000$53,000
Stock-based compensation$36.04M$37.82M$30.44M$27.96M$24.38M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.